Recombinant Rat LILRC1 Protein, CF

When Recombinant Rat LILRC1 (Catalog # 9698‑T4) is immobilized at 2 μg/mL, 100 μL/well, Recombinant Human Angiopoietin‑like Protein 7/ANGPTL7 (Catalog # 914‑AN) binds with an ED50 of 0.05‑0.3 μg/mL.

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat LILRC1 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Rat LILRC1 is immobilized at 2 μg/mL, 100 μL/well, Recombinant Human Angiopoietin‑like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED₅₀ of 0.05-0.3 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived rat LILRC1 protein
  Gln17-Asn248, with a C-terminal 6-His tag
• Accession #: NP_001070261
• N-terminal Sequence: No results obtained. Gln17 inferred from enzymatic pyroglutamate treatment revealing Glu18
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 27 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 34-41 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat LILRC1 Protein, CF

• E030017K20;EG232801;Gm4878;Lilra5
• LILRA5
• LILRC1

Background

The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs) (1). LILRC1 (leukocyte immunoglobulin-like receptor C1), also known as LILRA5, ILT11, LIR-9, and CD85f, consists of an extracellular domain (ECD), a transmembrane segment, and a cytoplasmic tail (2, 3). The ECD contains two Ig-like domains (4), and the transmembrane segment contains a positively charged arginine residue which may mediate its association with the signaling molecule, FcR common gamma chain (3, 5). Within the ECD, rat LILRC1 shares 58% and 85% amino acid sequence identity with human and mouse LILRA5, respectively. LILRC1 is expressed by monocytes, macrophages, and neutrophils (2, 3, 5). It is found as an approximately 40 kDa molecule on the cell surface, while a soluble 25 kDa form can be released into the synovial fluid of rheumatoid arthritis patients (2, 5). Cross-linking of LILRC1 on monocytes induces the expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) as well as the anti-inflammatory IL-10 (2, 5). R&D Systems in-house testing indicates that LILRC1/LILRA5 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (6).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Borges, L. et al. (2003) Blood 101:1484.
3. Hoelsbrekken, S.E. et al. (2005) Immunogenetics 57:479.
4. Shiroishi, M. et al. (2006) J. Biol. Chem. 281:19536.
5. Mitchell, A. et al. (2008) Eur. J. Immunol. 38:3459.
6. Zheng, J. et al. (2012) Nature 485:656.

Bioinformatics

• Uniprot:
  • NP_001070261()